Skip to Content
MilliporeSigma
All Photos(1)

Documents

M-136

Supelco

Methotrexate solution

1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C20H22N8O5
CAS Number:
Molecular Weight:
454.44
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol with 0.1N NaOH

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

SMILES string

O=C(C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)NC(C(O)=O)CCC(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)

InChI key

FBOZXECLQNJBKD-UHFFFAOYSA-N

General description

A Certified Spiking Solution® for use in therapeutic drug monitoring (TDM) analyses by HPLC or LC/MS. Used in the treatment of cancer and autoimmune diseases, methotrexate is an antimetabolite and antifolate drug monitored by clinical labs to ensure patients remain within the drug′s therapeutic range. The Snap-N-Spike® format allows laboratories to eliminate weighing operations of hazardous substances such as methotrexate, significantly reducing occupational exposure hazards related to handling of acutely toxic powders, and provides the ability to spike into their matrix of choice just before use.

Application


  • Pharmacokinetic analysis: Methotrexate solution is employed in advanced pharmacokinetic studies using UV-Vis spectrophotometric and colorimetric methods. This application facilitates precise quantification in plasma and tissue, crucial for evaluating drug distribution and effectiveness in cancer treatments (Febrianti et al., 2024).

  • Toxicity and safety monitoring: Observational studies utilize Methotrexate solution to investigate root causes of medication errors and manage toxicity in elderly patients. This research supports safer clinical practices by identifying risk factors and improving patient safety protocols (Bisht et al., 2024).

  • Nephrotoxicity prevention: Research on Methotrexate solution examines hydration strategies to mitigate nephrotoxicity, enhancing therapeutic outcomes. This study is pivotal in optimizing Methotrexate use in clinical settings, ensuring higher safety and efficacy for patients undergoing chemotherapy (Hasanpour et al., 2024).


Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Met. Corr. 1 - STOT SE 1

target_organs

Eyes,Central nervous system

wgk_germany

WGK 2

flash_point_f

closed cup

flash_point_c

closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 3

1 of 3

Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Daniel H Solomon et al.
The American journal of medicine, 126(8), 730-730 (2013-07-28)
Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). Subjects with rheumatoid
Richard Conway et al.
Arthritis & rheumatology (Hoboken, N.J.), 66(4), 803-812 (2014-04-24)
Methotrexate has shown efficacy for the treatment of several diseases, especially rheumatoid arthritis (RA). Methotrexate has also been implicated as a causative agent in interstitial lung disease. Patients with RA may develop pulmonary manifestations of their disease and are at
American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
Jonathan P Terdiman et al.
Gastroenterology, 145(6), 1459-1463 (2013-11-26)
James R O'Dell et al.
The New England journal of medicine, 369(4), 307-318 (2013-06-13)
Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate--a common scenario in the management of rheumatoid arthritis. We

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service